Amarin Corp PLC (AMRN) stock
Close on Nov 11, 2026Market cap $258.85MP/E –Yield –
Amarin Corp PLC saw revenue fall 22.3% to $176.11M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $258.85M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $258.85M
- P/E ratio
- –
- Price to sales
- 1.47
- Price to book
- 0.58
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $176.11M
- Net income
- -$19.14M
- EPS, diluted
- -$0.05
- Book value per share
- $1.04
- Diluted shares
- 428M
Trading
- Next earnings
- Feb 24, 2027 (estimated, before the open)
- Previous close
- $11.75
- Open
- $11.75
- Day's range
- $11.58 – $11.82
- Volume
- 81,286
- Average volume (20 days)
- 81,203
- Beta (5 years)
- 1.55
- 52-week range
- $11.25 – $17.31
- RSI (14 days)
- 42.1
- Volatility (1 year)
- 40.9%
- Relative volume
- 1.16×
- WACC
- 12.6%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AMRN | S&P 500 | Difference | AMRN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.7% | -2.4% | −0.3 pts | ||
| 3 months | -16.4% | -1.2% | −15.3 pts | ||
| Year to date | -16.1% | +12.3% | −28.4 pts | ||
| 1 year | -27.2% | +12.4% | −39.7 pts | ||
| 3 years | -18.7% | +78.8% | −97.5 pts | -6.7% | +21.4% |
| 5 years | -85.8% | +75.2% | −160.9 pts | -32.3% | +11.9% |
| 10 years | -81.5% | +311.1% | −392.6 pts | -15.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Amarin filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Amarin
Pharmaceutical Preparations
Amarin Corporation plc is a pharmaceutical enterprise focused on developing and commercializing therapeutic medicines, primarily featuring its product Vascepa (also designated as Vazkepa). The organization operates across segments that encompass product sales alongside licensing and royalty activities, distributing treatments and partnering internationally with entities such as Recordati, Biologix, Edding, CSL Seqirus, and HLS Therapeutics. Its commercial and distribution channels serve healthcare markets through out-licensing collaborations and commercial arrangements.
Company profile, executives and historyAmarin stock: common questions
What is Amarin's stock price?
AMRN closed at $11.71 on Nov 11, 2026, down 0.34% on the day. Over the past 52 weeks it traded between $11.25 and $17.31.
What is Amarin's market cap?
Amarin was worth $258.85M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AMRN's P/E ratio?
Amarin lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.05), so it has no meaningful P/E ratio.
How much revenue does Amarin make?
Amarin reported revenue of $176.11M for the twelve months to Sep 30, 2026, down 22.3% from a year earlier.
Does Amarin pay a dividend?
No. Amarin has not paid a cash dividend over the last twelve months.
When does Amarin report earnings next?
Amarin is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AMRN stock performed over the past year?
Including dividends, AMRN returned -27.2% over the past year, against +12.4% for the S&P 500.
Who are Amarin's competitors?
Companies most similar to Amarin by business, industry and size include KPTI, LGND, AKBA, ZVRA, KMDA.
See a number that looks wrong?